Serum GFAP as a biomarker for disease severity in multiple sclerosis.
Serum GFAP as a biomarker for disease severity in multiple sclerosis.
复制标题
DOI：
10.1038/s41598-018-33158-8
复制
发表时间：
2018-10-04
影响因子：
4.6
通讯作者：
Otto M
中科院分区：
文献类型：
--
作者：
Abdelhak A;Huss A;Kassubek J;Tumani H;Otto M
虽然血清中神经丝轻链（NfL）的测量是多发性硬化症（MS）中神经轴突损伤的一个公认的标志物，但血清中星形胶质标志物的数据缺失。本研究采用Simoa技术测定MS及其他非炎性神经疾病（OND）患者脑脊液（CSF）和血清中的胶质原纤维酸蛋白（GFAP）和NfL。临床数据如年龄、性别、扩展残疾状态量表（EDSS）和MRI结果与神经化学标志物相关。我们纳入了80例MS患者：42例复发缓解型MS (RRMS)， 38例进行性MS (PMS)，以及20例OND。PMS组血清GFAP水平高于RRMS组和OND组（p < 0.001, p = 0.02）。在整个MS组和PMS组中，血清GFAP水平与疾病严重程度相关（Spearman-rho = 0.5，两组p < 0.001）。经前综合征患者血清GFAP与血清NfL相关（Spearman-rho = 0.4, p = 0.01）。血清GFAP水平随着mri病变计数的增加而升高（p = 0.01）。总之，我们报道多发性硬化症患者血清中GFAP水平升高。由于血清GFAP水平与临床严重程度评分和MRI病变计数相关，特别是在经前综合征患者中，它可能是一个合适的疾病进展标志。
While neurofilament light chain (NfL) measurement in serum is a well-established marker of neuroaxonal damage in multiple sclerosis (MS), data on astroglial markers in serum are missing. In our study, glial fibrillary acid protein (GFAP) and NfL were measured in cerebrospinal fluid (CSF) and serum of MS patients and patients with other non-inflammatory neurological diseases (OND) using the Simoa technology. Clinical data like age, gender, expanded disability status scale (EDSS) and MRI findings were correlated to neurochemical markers. We included 80 MS patients: 42 relapsing-remitting MS (RRMS), 38 progressive MS (PMS), as well as 20 OND. Serum GFAP levels were higher in PMS compared to RRMS and OND (p < 0.001, p = 0.02 respectively). Serum GFAP levels correlated with disease severity in the whole MS group and PMS (Spearman-rho = 0.5, p < 0.001 in both groups). Serum GFAP correlated with serum NfL in PMS patients (Spearman-rho = 0.4, p = 0.01). Levels of serum GFAP were higher with increasing MRI-lesion count (p = 0.01). in summary, we report elevated levels of GFAP in the serum of MS patients. Since serum levels of GFAP correlate with the clinical severity scores and MRI lesion count, especially in PMS patients, it might be a suitable disease progression marker.
登录
查看更多内容
影响因子：
5.6
作者：
Abdelhak A;Junker A;Brettschneider J;Kassubek J;Ludolph AC;Otto M;Tumani H
通讯作者：
Tumani H
影响因子：
5.8
作者：
Manouchehrinia, Ali;Westerlind, Helga;Hillert, Jan
通讯作者：
Hillert, Jan
影响因子：
3.3
作者：
Madeddu, Roberto;Farace, Cristiano;Montella, Andrea
通讯作者：
Montella, Andrea
影响因子：
2.5
作者：
Kassubek, Rebecca;Gorges, Martin;Tumani, Hayrettin
通讯作者：
Tumani, Hayrettin
星形胶质细胞在多发性硬化症进展中的作用。
影响因子：
3.4
作者：
Correale J;Farez MF
通讯作者：
Farez MF